News & Events

April 2020

April 1, 2020 FUJIFILM Irvine Scientific to Sell FUJIFILM Cellular Dynamics iCell Products

Madison, Wis./ Irvine, Calif., March 31, 2020— FUJIFILM Cellular Dynamics, Inc. (FCDI), a leading developer and manufacturer of human induced pluripotent stem cells (iPSCs) and differentiated tissue-specific iPSCs, and FUJIFILM Irvine Scientific, Inc., a leader in cell culture media, announced that beginning April 1, 2020 iCell® products will be sold by the FUJIFILM “Discovery Research” organization (part of FUJIFILM Irvine Scientific).

March 2020

March 2, 2020 FUJIFILM Cellular Dynamics Begins Operations for Advanced Cell Therapies at its New Facility
Download PDF

MADISON, Wis., March 2, 2019 — FUJIFILM Cellular Dynamics, Inc. (FCDI), a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC) technologies, will begin operation of its new cGMP-compliant iPSC production facility on March 4. The new facility called “Innovation Facility for Advanced Cell Therapy” (i-FACT), will house development, and manufacture of iPSCs for therapeutic applications. The i-FACT will enable FCDI to accelerate the development of its own pipeline of regenerative medicine therapies using iPSCs, and it will also serve as a Contract Development and Manufacturing Organization (CDMO) of IPSCs and iPSC-derived differentiated cells.   See the video press release.

December 2019

December 5, 2019 Fujifilm Establishes the Bio Science & Engineering Laboratories U.S.A. to Start Full-scale Translational Research for Biotherapeutics in the United States

Strengthening fundamental research capabilities in the areas of gene therapy, cell therapy and regenerative medicine applications, and promoting industry-leading advanced research by incorporating cutting-edge technologies in the U.S. and fusing the group technologies

Tokyo, December 5, 2019― FUJIFILM Corporation (President: Kenji Sukeno) announced that it has begun full-scale research activities to advance the field of translational research for biotherapeutics at its newly established “Bio Science & Engineering Laboratories U.S.A.” (“US Bio Center”) located in Madison, Wisconsin. The goal of the Fujifilm US Bio Center will be to further strengthen its fundamental research efforts to support the broad goals of Fujifilm in the areas gene therapy, cell therapy and regenerative medicine applications.

July 2019

July 10, 2019 Fujifilm and Axcelead Drug Discovery Partners Begin Collaborating to Advance Drug Discovery Solutions Using iPSCs

To enhance the Process of Research and Development of Drug Candidates

Tokyo/Kanagawa, July 10, 2019 ―FUJIFILM Corporation (President: Kenji Sukeno; Fujifilm) and Axcelead Drug Discovery Partners, Inc. (President: Yoshinori Ikeura; Axcelead) announced a collaboration to provide customers with a human induced pluripotent stem cell (iPSC)-based integrated platform for drug discovery solutions. By combining Fujifilm’s iPSC-derived products that its U.S. subsidiary FUJIFILM Cellular Dynamics Inc. (FCDI) offers and Axcelead’s compound evaluation and analytical services, the companies will work towards developing new drug efficacy evaluation methods and toxicity testing to meet specific needs of clients.

July 1, 2019 Century Therapeutics Launches with $250M Financing for iPSC Allogeneic Cell Therapy Platform

Tokyo, June 1, 2019 ― FUJIFILM Corporation (President: Kenji Sukeno) will accelerate the development of next-generation cancer immunotherapeutic drug candidates by harnessing the self-renewal potential of allogenic induced pluripotent stem cells (iPSCs). FUJIFILM Cellular Dynamics, Inc. (FCDI), a leading developer and manufacturer of human iPSCs and tissue-specific cells differentiated from iPSCs, and Versant Venture Management,…

January 2019

January 8, 2019 FUJIFILM Cellular Dynamics Inc. Launches New Product iCell Microglia, an iPSC-Derived Neural Cell TypeDownload PDF

hiPSC-derived microglia are utilized with the aim of advancing research to fulfill unmet medical needs for patients with neurodegenerative diseases

 MADISON, Wis., January 08, 2019 — FUJIFILM Cellular Dynamics, Inc. (FCDI), a leading developer and manufacturer of human induced pluripotent stem cells (iPSCs) and tissue-specific cells differentiated  from iPSCs, has announced the launch of its newest product, iCell® Microglia. Microglia are the immune cells of the central nervous system responsible for fundamental physiological and pathological processes. Differentiated from human iPSCs, iCell Microglia will be used in life science research to enable the study and development of therapies for degenerative neurological diseases such as Alzheimer’s disease…

January 3, 2019 FUJIFILM Cellular Dynamics to Establish New Facility for Production of Human iPS Cell Therapy ApplicationsDownload PDF

Fujifilm is investing in the cGMP-compliant facility located in Madison, Wisconsin with the goal to begin operations by March 2020

MADISON, Wis., January 3, 2019 — FUJIFILM Cellular Dynamics, Inc. (FCDI), a US subsidiary of FUJIFILM Corporation (President: Kenji Sukeno) and a leading global developer and manufacturer of human induced pluripotent stem (iPS) cell technologies, has announced an investment of about $21 million to open a new cGMP-compliant  production facility with the goal of industrializing iPS cell manufacturing for regenerative medicine therapies. The facility will support FCDI’s internal cell therapeutics pipeline and will also serve as a Contract Development and Manufacturing Organization (CDMO) for iPS cell products.

June 2018

June 6, 2018 Fujifilm Cellular Dynamics Announces Agreement with UCI to Commercialize iPSC-Derived Microglia and Media Formulation

FUJIFILM Cellular Dynamics, Inc., licenses University of California – Irvine’s technologies for derivation of microglia

MADISON, Wis., June 6, 2018— FUJIFILM Cellular Dynamics, Inc. (FCDI), a leading developer and manufacturer of human induced pluripotent stem cells (iPSCs) and differentiated tissue-specific iPSCs, announced today that it has entered into an exclusive patent license agreement with the University of California – Irvine (UCI) through its offices at UCI Applied Innovation to license and commercialize UCI’s technologies for derivation of microglia in the commercial research field and also a non-exclusive patent license agreement to commercialize microglia media formulation. The license of UCI’s groundbreaking technology enables FCDI to differentiate pluripotent stem cells into microglia cells, a brain cell type that plays a critical role in preserving the function of the brain. With this technology, FCDI intends to develop an iPSC-derived microglia product with media, which will be critical to enabling the study of degenerative neurological diseases such as Alzheimer’s disease.

February 2018

February 8, 2018 Fujifilm and Takeda Announce Collaboration to Develop Regenerative Medicine Therapies using Cardiomyocytes Derived from iPSC

February 8, 2018 – FUJIFILM Corporation (“Fujifilm”, President: Kenji Sukeno) and Takeda Pharmaceutical Company Ltd., (“Takeda”, CEO: Christophe Weber) today announced a collaboration to develop regenerative medicine therapies using cardiomyocytes derived from iPSC for the treatment of heart failure.

December 2017

December 22, 2017 Cellular Dynamics International Sends Human iPSC-Derived Cardiomyocytes To International Space Station On NASA Resupply Mission

MADISON, Wis., Dec. 27, 2017 — Cellular Dynamics International (CDI), a FUJIFILM company, the leading developer and manufacturer of human induced pluripotent stem cells (iPSCs) and differentiated tissue-specific iPSC-cells, announced that its iCell® Cardiomyocytes were launched into space via SpaceX’s 13th commercial resupply services mission to the International Space Station on Dec.15, 2017. The purpose of the scientific research project utilizing CDI’s iCell Cardiomyocytes in space is to validate the function of NASA’s new Bioculture System for automated cell culture on the International Space Station and to study human cardiac cell function in microgravity.

Pageof 5